Navigation Links
After Treatment for Precancerous Cervical Lesions, Risk Drops to Normal for Some
Date:4/28/2011

By Steven Reinberg
HealthDay Reporter

THURSDAY, April 28 (HealthDay News) -- Women who have been treated for precancerous cervical lesions should see their cancer risk drop to normal after three "all clear" screening test results, Dutch researchers say.

These women can then resume screening for cervical cancer on the same schedule as the general population, they added.

"The question is how we should follow women who have been treated for precancerous cervical lesions," said lead researcher Dr. Chris Meijer, from the department of pathology at Vrije University Medical Center in Amsterdam.

The answer appears linked to two years worth of normal test results following treatment.

In the study, Meijer's team looked at the effectiveness of follow-up screening among 435 women who were treated for precancerous cervical lesions between July 1988 and November 2004. The women were given Pap tests to screen for cervical cancer and also tested for a virus linked to the cancer -- human papillomavirus, or HPV -- at 6, 12 and 24 months after treatment. If the test results were normal, they resumed normal testing, which in the Netherlands is once every five years.

The risk of developing new precancerous cervical lesions or cervical cancer over five years was 16.5 percent.

However, among women who had three normal Pap and HPV tests, the risk dropped to 3 percent in the same period, which is the same risk seen in women who never had precancerous cervical lesions, the researchers noted.

In addition, Meijer's group found that adding HPV testing made the one year screening unnecessary for women who had had a negative test at six months.

Women treated for precancerous cervical lesions who develop recurring disease need to be screened with Pap and human papillomavirus testing, but the best regimen for long-term follow-up hasn't been clear, the researchers said.

The report was published in the April 27 online edition of The Lancet Oncology.

The American Congress of Obstetricians and Gynecologists recommends that women aged 21 to 30 be screened for cervical cancer every two years and that women over 30 who have had three negative (normal) Pap and HPV tests in a row be screened every three years.

Meijer thinks that even though the protocol for screening women over 30 in the United States is every three years, it can safely be extended to five years.

However, women who have abnormal tests after treatment need additional testing, because their risk of developing the disease again is high over the next five years, Meijer noted.

Commenting on the study, Dr. Elizabeth A. Poynor, a gynecologic oncologist and pelvic surgeon at Lenox Hill Hospital in New York City said that "this provides a framework for how to follow people after they have been treated for precancerous cervical lesions."

For Poynor, the important message is that if a women does not have a recurrence after two years, her risk of developing precancerous cervical lesions reverts to the same risk as women who have never had precancerous cervical lesions -- that is, they have the same risk as other women in the general population.

"These women can go back to accepted population screening in the United States, which is a little bit more stringent [than that in the Netherlands]," she said. "Women two years after being appropriately treated for precancerous cervical lesions can be reassured that they go back down to a population risk."

More information

For more information on cervical cancer, visit the U.S. National Cancer Institute.

SOURCES: Chris Meijer, M.D., Ph.D., department of pathology,Vrije University Medical Center, Amsterdam; Elizabeth A. Poynor, M.D., Ph.D., gynecologic oncologist and pelvic surgeon, Lenox Hill Hospital, New York City; April 27, 2011, The Lancet Oncology, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. One Month after Major Quake, Ongoing Crises for Haitian Children
2. Ex-President Clinton Said To Be Fine After Heart Procedure
3. Bill Clinton Back Home After Heart Procedure
4. After a Stroke, High Risk for a Recurrence
5. Women Need More Help After Heart Attack
6. Afternoon Nap Might Make You Smarter
7. Access to Mammograms Drops After Guidelines Change
8. Two Babies Born a Year Apart After Ovary Transplant
9. Vitamin B3 May Help Repair Brain After a Stroke
10. HIV drug that protects a fetus should be avoided for one year after childbirth, researchers say
11. Doctor Joseph Racanelli is Helping Christina Get Back Her Shape After Brutal Attack
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
After Treatment for Precancerous Cervical Lesions, Risk Drops to Normal for Some
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium determination is consistently becoming ... require expert user knowledge. In a live webinar on April 11th and October ... highly accurate, determination of sodium. , It has long been known that too ...
(Date:3/27/2017)... Fla. (PRWEB) , ... March 27, 2017 , ... ... overdose deaths soared 167%,(1) with opioids alone responsible for over 33,000 of the ... McCarty has sponsored Assembly Bill (AB) 1512, which proposes a tax on prescription ...
(Date:3/25/2017)... ... , ... Getting earned media coverage meaningful for Garden Media Group's clients is ... year, Garden Media aims to provide material helpful to clients’ goals and bottom lines. ... key messages to gain coveted media placements, Garden Media wows clients year-round. , ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mediaplanet today announces ... on the current obstacles facing infection prevention and offer strategies for the health ... these infections. , The print component of “Fighting Infection” is distributed within ...
(Date:3/24/2017)... ... ... According to a new study by NCPA Senior Fellow John R. Graham, ... Congress has directed the CBO to follow. The CBO itself previously recognized Obamacare would ... estimates a reduction in employer-based coverage due to the GOP reform, which is not ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), ... successfully passed early toxicology and efficacy studies. The company ... target a specific protein, MAGE A, in an effort ... cancer. After 4 weeks of treatment ... show very little toxicity in a full toxicology report ...
(Date:3/27/2017)... 2017  Sanderling Ventures, portfolio company, Torax Medical, ... of Johnson & Johnson. Torax manufactures and markets the ... gastro-esophageal reflux disease (GERD). The LINK device is ... the procedure is currently available in the U.S. ... was founded by Sanderling Ventures, Mayo Medical Ventures ...
(Date:3/27/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... an immunotherapy for the treatment of multiple cancers, obtained through ... at the upcoming American Association for Cancer Research (AACR) ... to be held on April 1-5, 2017. ... An abstract titled ...
Breaking Medicine Technology: